Nadia Harbeck
YOU?
Author Swipe
View article: ER+/HER-2 NEG ABC – NEWS SINCE ABC7
ER+/HER-2 NEG ABC – NEWS SINCE ABC7 Open
View article: INVESTIGATING THE IMPORTANCE OF PATIENT-PHYSICIAN-COMMUNICATION FOR SUCCESSFUL TREATMENT OF METASTATIC BREAST CANCER: THE WAVES STUDY
INVESTIGATING THE IMPORTANCE OF PATIENT-PHYSICIAN-COMMUNICATION FOR SUCCESSFUL TREATMENT OF METASTATIC BREAST CANCER: THE WAVES STUDY Open
View article: Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial Open
In DESTINY-Breast04 ( NCT03734029 ), trastuzumab deruxtecan (T-DXd) significantly improved overall survival (OS) and progression-free survival compared with treatment of physician's choice of chemotherapy (TPC) for patients with human epid…
View article: Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial
Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial Open
What is this summary about?
View article: Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy Open
In the randomized, phase 3 KEYNOTE-119 study, overall survival (OS) was not significantly improved with pembrolizumab 200 mg Q3W versus investigator’s choice of chemotherapy in participants with previously treated metastatic TNBC. In this …
View article: ESMO guidance on the use of Large Language Models in Clinical Practice (ELCAP)
ESMO guidance on the use of Large Language Models in Clinical Practice (ELCAP) Open
ELCAP provides a three-tier framework and basic practical guidance for LLM use in oncology. ESMO supports efforts to use this framework to improve patient care, but warns against unsupervised or unvalidated use.
View article: Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial Open
Neoadjuvant T-DXd-THP demonstrated statistically significant and clinically meaningful pCR benefit and improved safety versus ddAC-THP.
View article: The Janus Face of <scp>SPAG6</scp>: Inducing <scp>EMT</scp> in Luminal Breast Cancer Cells Amidst Widespread Expression Loss in Breast Tumours
The Janus Face of <span>SPAG6</span>: Inducing <span>EMT</span> in Luminal Breast Cancer Cells Amidst Widespread Expression Loss in Breast Tumours Open
Understanding the role and molecular regulation of genes associated with tumour cell motility may be informative for future cancer therapy development. Sperm‐associated antigen 6 ( SPAG6 ) gene, encoding an evolutionarily highly conserved …
View article: Attitudes toward AI-generated risk prediction in patients with early breast cancer: an international multicenter survey
Attitudes toward AI-generated risk prediction in patients with early breast cancer: an international multicenter survey Open
View article: Real-world effectiveness and safety of CDK4/6i in elderly and BIPOC patients with HR+/HER2- advanced/metastatic breast cancer: an updated systematic literature review
Real-world effectiveness and safety of CDK4/6i in elderly and BIPOC patients with HR+/HER2- advanced/metastatic breast cancer: an updated systematic literature review Open
Background and aim The HR-positive/HER2-negative (HR+/HER2-) advanced/metastatic breast cancer (a/mBC) treatment landscape has advanced with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), yet outcome disparities persist, particularly am…
View article: Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials
Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials Open
This pooled analysis demonstrates that neoadjuvant de-escalation trials with further pCR-adapted treatment (de-)escalation are feasible and appear safe for HER2-positive eBC patients. Twelve-weekly neoadjuvant paclitaxel plus HER2 blockade…
View article: Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)
Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292) Open
When comparing central and local Ki67 assessments in the large multicenter randomized WSG ADAPTcycle trial, we observed similar rates of ET responders. The agreement between local and central Ki67 assessments at BL and post-endocrine treat…
View article: CDK4/6‐Inhibitor in Kombination mit Aromatasehemmer wirksam bei metastasiertem Hidradenokarzinom
CDK4/6‐Inhibitor in Kombination mit Aromatasehemmer wirksam bei metastasiertem Hidradenokarzinom Open
View article: A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders
A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders Open
BACKGROUNDEndocrine therapy (ET) with tamoxifen (TAM) or aromatase inhibitors (AI) is highly effective against hormone receptor-positive (HR-positive) early breast cancer (BC), but resistance remains a major challenge. The primary objectiv…
View article: Erratum zu: Digitale Begleitung der Therapie und Nachsorge beim Mammakarzinom
Erratum zu: Digitale Begleitung der Therapie und Nachsorge beim Mammakarzinom Open
View article: Integrative analysis of pre-treatment RNA expression signatures and recurrent genomic alterations: Link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer
Integrative analysis of pre-treatment RNA expression signatures and recurrent genomic alterations: Link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer Open
Background Endocrine therapy with tamoxifen (TAM) or aromatase inhibitors (AI) is an effective treatment for patients with estrogen receptor-positive, HER2-negative luminal breast cancer. However, many patients do not respond to this thera…
View article: Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial Open
View article: Palbociclib: randomisierte Studien und Real-World-Evidenz als Grundlage für die Therapieplanung beim metastasierten Mammakarzinom
Palbociclib: randomisierte Studien und Real-World-Evidenz als Grundlage für die Therapieplanung beim metastasierten Mammakarzinom Open
Zusammenfassung Die endokrin basierte Kombinationstherapie mit einem Inhibitor der cyclinabhängigen Kinasen 4 und 6 (CDK4/6-Inhibitor) gilt heute als Erstlinientherapie der ersten Wahl für Patientinnen und Patienten mit hormonrezeptorposit…
View article: Breast cancer in patients under 40 years: an 11-year retrospective cohort analysis
Breast cancer in patients under 40 years: an 11-year retrospective cohort analysis Open
Introduction The number of young breast cancer (BC) patients is increasing in both high- and low-income countries. It is known that this population is at risk for more aggressive tumor phenotypes, larger tumor size at diagnosis and poorer …
View article: St. Gallen/Vienna 2025 Summary of Key Messages on Therapy in Early Breast Cancer from the 2025 St. Gallen International Breast Cancer Conference
St. Gallen/Vienna 2025 Summary of Key Messages on Therapy in Early Breast Cancer from the 2025 St. Gallen International Breast Cancer Conference Open
Background: In 2025, the St. Gallen Conference was held from March 12th–15th, with the largest attendance since the pandemic and more than 3,000 participants from over 100 countries. Summary: The conference chairs professionally guided thr…
View article: 194P Efficacy and safety of abemaciclib in younger patients with early breast cancer in the monarchE trial
194P Efficacy and safety of abemaciclib in younger patients with early breast cancer in the monarchE trial Open
View article: Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC Open
Background The phase 3 DESTINY-Breast04 trial demonstrated superior efficacy and acceptable safety with trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy in previously treated patients with human epidermal growth factor …
View article: Update Breast Cancer 2024 Part 3 – Patients with Advanced Stage Breast Cancer
Update Breast Cancer 2024 Part 3 – Patients with Advanced Stage Breast Cancer Open
The use of CDK4/6 inhibitors, the new PI3K/AKT-kinase inhibitors, selective estrogen receptor-degraders (SERDs), antibody-drug conjugates, immune therapies and PARP inhibitors in recent years has resulted in a marked change in the therapy …
View article: Update Breast Cancer 2024 Part 2 – Patients with Early Stage Breast Cancer
Update Breast Cancer 2024 Part 2 – Patients with Early Stage Breast Cancer Open
This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negati…
View article: 9P Clinical and translational markers for predicting survival in a pooled analysis of three de-escalated neoadjuvant WSG trials in HER2+ early breast cancer
9P Clinical and translational markers for predicting survival in a pooled analysis of three de-escalated neoadjuvant WSG trials in HER2+ early breast cancer Open
View article: CDK4/6 inhibitor in combination with aromatase inhibitor effective in metastatic hidradenocarcinoma
CDK4/6 inhibitor in combination with aromatase inhibitor effective in metastatic hidradenocarcinoma Open
View article: Electric-Field Molecular Fingerprinting to Probe Cancer
Electric-Field Molecular Fingerprinting to Probe Cancer Open
Human biofluids serve as indicators of various physiological states, and recent advances in molecular profiling technologies hold great potential for enhancing clinical diagnostics. Leveraging recent developments in laser-based electric-fi…
View article: Systems epigenetic approach towards non-invasive breast cancer detection
Systems epigenetic approach towards non-invasive breast cancer detection Open
View article: Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial Open
NCT01815242.
View article: Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk Open
This analysis shows that treatment recommendation for AI + OFS in premenopausal patients with HRpos/HER2neg eBC increased relevantly in the past years, reflecting latest guideline recommendations.